These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 8024198)

  • 61. A novel potential effector of M-Ras and p21 Ras negatively regulates p21 Ras-mediated gene induction and cell growth.
    Ehrhardt GR; Korherr C; Wieler JS; Knaus M; Schrader JW
    Oncogene; 2001 Jan; 20(2):188-97. PubMed ID: 11313946
    [TBL] [Abstract][Full Text] [Related]  

  • 62. A mutant p53 protein is required for maintenance of the transformed phenotype in cells transformed with p53 plus ras cDNAs.
    Zambetti GP; Olson D; Labow M; Levine AJ
    Proc Natl Acad Sci U S A; 1992 May; 89(9):3952-6. PubMed ID: 1570319
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Inhibition of anchorage-independent growth of ras-transformed cells on polyHEMA surface by antisense oligodeoxynucleotides directed against K-ras.
    Kawada M; Fukazawa H; Mizuno S; Uehara Y
    Biochem Biophys Res Commun; 1997 Feb; 231(3):735-7. PubMed ID: 9070883
    [TBL] [Abstract][Full Text] [Related]  

  • 64. B-RAF and N-RAS mutations are preserved during short time in vitro propagation and differentially impact prognosis.
    Ugurel S; Thirumaran RK; Bloethner S; Gast A; Sucker A; Mueller-Berghaus J; Rittgen W; Hemminki K; Becker JC; Kumar R; Schadendorf D
    PLoS One; 2007 Feb; 2(2):e236. PubMed ID: 17311103
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Persistence of Ha-ras-induced metastatic potential of SP1 mouse mammary tumors despite loss of the Ha-ras shuttle vector.
    Schlatter B; Waghorne CG
    Proc Natl Acad Sci U S A; 1992 Nov; 89(21):9986-90. PubMed ID: 1438249
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Use of an anti-ras ribozyme to alter the malignant phenotype of a human bladder cancer cell line.
    Eastham JA; Ahlering TE
    J Urol; 1996 Sep; 156(3):1186-8. PubMed ID: 8709343
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Transfection of human mutated K-ras in mouse NIH-3T3 cells is associated with increased cloning efficiency and DNA aneuploidization.
    Nigro S; Geido E; Infusini E; Orecchia R; Giaretti W
    Int J Cancer; 1996 Sep; 67(6):871-5. PubMed ID: 8824561
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture.
    Giannini CD; Roth WK; Piiper A; Zeuzem S
    Nucleic Acids Res; 1999 Jul; 27(13):2737-44. PubMed ID: 10373591
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The influence of the oncogenes NRAS and MYC on the radiation sensitivity of cells of a human melanoma cell line.
    Pomp J; Ouwerkerk IJ; Hermans J; Wondergem J; Cornelisse CJ; Leer JW; Schrier PI
    Radiat Res; 1996 Oct; 146(4):374-81. PubMed ID: 8927709
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Requirement of estrogen receptor expression and function for [12Val] K-Ras-mediated NIH3T3 cell transformation.
    Kato K; Sakamoto T; Wake N
    Oncology; 1998 Dec; 55 Suppl 1():45-52. PubMed ID: 9852401
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Ribozyme as an approach for growth suppression of human pancreatic cancer.
    Kijima H; Scanlon KJ
    Mol Biotechnol; 2000 Jan; 14(1):59-72. PubMed ID: 10911615
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Oncogenes as inducers of tumor angiogenesis.
    Rak J; Filmus J; Finkenzeller G; Grugel S; Marmé D; Kerbel RS
    Cancer Metastasis Rev; 1995 Dec; 14(4):263-77. PubMed ID: 8821090
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Targeted tumor killing via an intracellular antibody against erbB-2.
    Deshane J; Siegal GP; Alvarez RD; Wang MH; Feng M; Cabrera G; Liu T; Kay M; Curiel DT
    J Clin Invest; 1995 Dec; 96(6):2980-9. PubMed ID: 8675670
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Antigene, ribozyme and aptamer nucleic acid drugs: progress and prospects.
    Stull RA; Szoka FC
    Pharm Res; 1995 Apr; 12(4):465-83. PubMed ID: 7596980
    [TBL] [Abstract][Full Text] [Related]  

  • 75. H-ras ribozyme-mediated alteration of the human melanoma phenotype.
    Ohta Y; Tone T; Shitara T; Funato T; Jiao L; Kashfian BI; Yoshida E; Horng M; Tsai P; Lauterbach K
    Ann N Y Acad Sci; 1994 May; 716():242-53; discussion 253-6. PubMed ID: 8024198
    [No Abstract]   [Full Text] [Related]  

  • 76. Tissue-specific expression of an anti-ras ribozyme inhibits proliferation of human malignant melanoma cells.
    Ohta Y; Kijima H; Ohkawa T; Kashani-Sabet M; Scanlon KJ
    Nucleic Acids Res; 1996 Mar; 24(5):938-42. PubMed ID: 8600463
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes.
    Ohta Y; Kijima H; Kashani-Sabet M; Scanlon KJ
    J Invest Dermatol; 1996 Feb; 106(2):275-80. PubMed ID: 8601728
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Reversal of the malignant phenotype by an anti-ras ribozyme.
    Kashani-Sabet M; Funato T; Tone T; Jiao L; Wang W; Yoshida E; Kashfinn BI; Shitara T; Wu AM; Moreno JG
    Antisense Res Dev; 1992; 2(1):3-15. PubMed ID: 1422085
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Synthesis and functional studies on nucleic acids. Problems related to synthetic ras genes].
    Ohtsuka E
    Yakugaku Zasshi; 1994 Oct; 114(10):747-64. PubMed ID: 7807379
    [TBL] [Abstract][Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.